M
Mark D. Minden
Researcher at Princess Margaret Cancer Centre
Publications - 471
Citations - 25915
Mark D. Minden is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 67, co-authored 407 publications receiving 22943 citations. Previous affiliations of Mark D. Minden include University Health Network & Mount Sinai Hospital, Toronto.
Papers
More filters
Journal ArticleDOI
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Tsvee Lapidot,Christian Sirard,Josef Vormoor,Barbara Murdoch,Trang Hoang,Julio R. Caceres-Cortes,Mark D. Minden,Bruce Paterson,Michael A. Caligiuri,John E. Dick +9 more
TL;DR: This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.
Journal ArticleDOI
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush,Sasan Zandi,Amanda Mitchell,Weihsu Claire Chen,Joseph M. Brandwein,Vikas Gupta,James A. Kennedy,Aaron D. Schimmer,Andre C. Schuh,Karen W.L. Yee,Jessica McLeod,Monica Doedens,Jessie J. F. Medeiros,Rene Marke,Hyeoung Joon Kim,Kwon Lee,John Douglas Mcpherson,Thomas J. Hudson,Andrew M.K. Brown,Fouad Yousif,Quang M. Trinh,Lincoln Stein,Mark D. Minden,Jean C.Y. Wang,John E. Dick +24 more
TL;DR: Highly purified haematopoietic stem cells, progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts.
Journal ArticleDOI
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian,Xavier Thomas,Anna Dmoszynska,Agnieszka Wierzbowska,Grzegorz Mazur,Jiri Mayer,Jyh Pyng Gau,Wen-Chien Chou,Rena Buckstein,Jaroslav Cermak,Ching Yuan Kuo,Albert Oriol,Farhad Ravandi,Stefan Faderl,Jacques Delaunay,Daniel Lysák,Mark D. Minden,Christopher Arthur +17 more
TL;DR: In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
Journal ArticleDOI
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret,John F. Seymour,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Giovanni Martinelli,Jose F Falantes,Richard Noppeney,Richard Stone,Mark D. Minden,Heidi McIntyre,S. Songer,Lela M. Lucy,C.L. Beach,Hartmut Döhner +23 more
TL;DR: Univariate analysis showed favorable trends for azacitidine compared with CCR across all subgroups defined by baseline demographic and disease features, and adverse events were consistent with the well-established safety profile of azacItidine.
Journal ArticleDOI
Stem cell gene expression programs influence clinical outcome in human leukemia
Kolja Eppert,Katsuto Takenaka,Eric R. Lechman,Levi Waldron,Björn Nilsson,Peter van Galen,Klaus H. Metzeler,Armando G. Poeppl,Vicki Ling,Joseph Beyene,Angelo J. Canty,Jayne S. Danska,Stefan K. Bohlander,Christian Buske,Mark D. Minden,Todd R. Golub,Igor Jurisica,Benjamin L. Ebert,John E. Dick +18 more
TL;DR: It is shown that acute myeloid leukemia (AML) follows a CSC model on the basis of sorting multiple populations from each of 16 primary human AML samples and identifying which contain leukemia stem cells (LSCs) using a sensitive xenograft assay, establishing that LSCs are clinically relevant and not artifacts of xenotransplantation.